Al­ler­gan bags two new deals, takes op­tion to buy Lyso­so­mal Ther­a­peu­tics and pays $50M for mi­cro­bio­me pact

Al­ler­gan swooped in­to JP Mor­gan bear­ing news of a pair of deals, ink­ing an ex­clu­sive op­tion to buy out Lyso­so­mal Ther­a­peu­tics for its neu­rode­gen­er­a­tion pipeline and pay­ing $50 mil­lion up­front to part­ner with As­sem­bly Bio on the mi­cro­bio­me.

Al­ler­gan bought the op­tion on Lyso­so­mal Ther­a­peu­tics — run by Kees Been — peg­ging an un­spec­i­fied price for the biotech af­ter the Phase Ib comes through with da­ta on Parkin­son’s dis­ease for their drug LTI-291. Al­ler­gan, which is not in the least bit re­luc­tant to pay a pre­mi­um for what it wants, al­so added some fi­nan­cial sup­port for R&D at the com­pa­ny, but de­clined to spell out the de­tails.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER